Azora Therapeutics, founded by a team with decades of drug development experience, is a clinical-stage biopharmaceutical company focused on creating innovative therapies for serious inflammatory diseases. The company's core mission is to harness the body's natural immune regulation to develop novel small-molecule chemical entities that treat autoimmune and inflammatory conditions such as hidradenitis suppurativa (HS) and ulcerative colitis (UC).
Notable figures affiliated with Azora Therapeutics include its co-founder and Chief Executive Officer, who has a significant track record in the pharmaceutical industry. The company has contributed to the development of groundbreaking medicines like Uceris®, Tysabri®, Ycanth®, and Humira®. Azora's key achievements include advancing its pipeline of therapeutic candidates and making impactful strides in treating debilitating inflammatory diseases.
